tirzepatide fda approval for weight loss Day 4: Zepbound (Tirzepatide – indication) Approved: November 2023 weight management Weight Loss: Up to 22.5% in clinical trials Similar to Mounjaro, but marketed specifically for weight management Introducing Tirzepatide NOW AVAILABLE at

At the highest dosage tier (15 mg), expect to pay around $387.98 per month on the standard monthly plan

Inside the Dual Hormone Mechanism Thats Redefining Obesity Treatment In the evolving story of GLP-1based therapeutics, tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity) represents a striking innovation: a drug designed not to mimic one hormone, but two

Klinic offers four FDA-approved medications for weight management: Zepbound (injectable tirzepatide, once weekly), Wegovy (injectable semaglutide, once weekly), Oral Wegovy (semaglutide tablet, once daily), and Foundayo (orforglipron tablet, once daily)

The dual agonist nature of tirzepatide, acting on both GIP and GLP-1 receptors, contributes to its efficacy in glycaemic control and weight management but also influences the gastrointestinal side effect profile

By mimicking GLP-1 and GIP hormones, it helps manage blood sugar and suppress appetite, leading to substantial weight loss for many patients

Not for All Patients Contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)